Luis Alvarez/DigitalVision via Getty Images Maravai LifeSciences ( NASDAQ: MRVI ) surged 18% after a report that Repligen ( NASDAQ: RGEN ) approached the company with a takeover offer. Repligen quickly dropped 7.4%.
There's no certainty that Maravai ( MRVI ) will accept the deal, according to a Reuters report on Friday, which cited people familiar with the matter. Repligen ( REGN ) is also deciding if it should divest some of Maravai's divisions if it acquires the vaccine reagent vendor. Repligen ( RGEN ) and Maravai ( MRVI ) spokespeople didn't immediately respond to Reuters request for comment.
Maravai has a market cap of $2 billion, while Repligen is valued at $9 billion. This isn't the first time Maravai ( MRVI ) has attracted takeover interest. Betaville last July reported that Germany's Merck KGaA ( OTCPK:MKGAF ) is speculated to be one of the companies looking at the vaccine reagent vendor.
Merck was rumored to have shown some interest in MRVI after reports it rejected an offer from private equity firm Thomas H. Lee. Reuters reported in February 2022 that German lab supplied vendor Sartorius ( OTCPK:SARTF ) made an $ 11 billion, or $42 a share, bid for the company.
More on Maravai LifeSciences Holdings, Repligen, etc. Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call Transcript Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript Repligen: Strong Filtration Growth, Offset By Other Challenges Maravai cut at Morgan Stanley; Pfizer/BioNTech headwind.